Treatment and Prognosis Based on Types and Stages of Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 胡建昆 , 陈心足

;

Corresponding author：

胡建昆, Email: hujkwch@126.com

Keywords：

胃癌; 治疗; 预后; 分型; HER2表型; 分期

DOI：

10.7507/1007-9424.20140001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 胡建昆, 陈心足. Treatment and Prognosis Based on Types and Stages of Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(1): 1-6. doi: 10.7507/1007-9424.20140001 Copy

1.	胡建昆,陈心足.进展期胃癌治疗方式合理选择及评价[J].中国实用外科杂志,2011,31(8):720-722.
2.	胡建昆,陈心足.胃癌多学科协作诊疗模式现状[J].中国普外基础与临床杂志,2012,19(1):1-3.
3.	Hu B,El Hajj N,Sittler S,et al.Gastric cancer:Classification,histology and application of molecular pathology[J].J Gastrointest Oncol,2012,3(3):251-261.
4.	何裕隆.胃癌病理分型研究进展[J].中国实用外科杂志,2005,25(7):438-440.
5.	Santiago JM,Sasako M,Osorio J.TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer.Tow-ards simplicity and standardisation in the management of gastric cancer[J].Cir Esp,2011,89(5):275-281.
6.	Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14(2):113-123.
7.	Liang YX,Guo HH,Deng JY,et al.Impact of intraoperative blood loss on survival after curative resection for gastric cancer[J].World J Gastroenterol,2013,19(33):5542-5550.
8.	Yang B,Wu G,Wang X,et al.Discussion of modifying stage Ⅳ gastric cancer based on Borrmann classification[J].Tumour Biol,2013,34(3):1485-1491.
9.	Sun XC,Lin J,Ju AH.Treatment of Borrmann type Ⅳ gastric cancer with a neoadjuvant chemotherapy combination of docetaxel,cisplatin and 5-fluorouracil/leucovorin[J].J Int Med Res,2011,39(6):2096-2102.
10.	Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.
11.	Sasako M,Sano T,Yamamoto S,et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial[J].Lancet Oncol,2006,7(8):644-651.
12.	Mine S,Sano T,Hiki N,et al.Proximal margin length with trans-hiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction[J].Br J Surg,2013,100(8):1050-1054.
13.	Lauren P.The two histological main types of gastric carcinoma:Diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification[J].Acta Pathol Microbiol Scand,1965,64:31-49.
14.	Lauwers GY,Carneiro F,Graham DY.Gastric carcinoma[A]//Bowman FT,Carneiro F,Hruban RH,eds.Classification of tumours of the digestive system[M].Lyon:IARC,2010.In press.
15.	李忠武,曹登峰.胃癌病理分型与临床个体化治疗——问题与展望[J].中国医学前沿杂志:电子版,2012,4(5):15-20.
16.	Liu L,Wang ZW,Ji J,et al.A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma[J].Anticancer Agents Med Chem,2013,13(2):227-234.
17.	Qiu MZ,Cai MY,Zhang DS,et al.Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China[J].J Transl Med,2013,11:58.
18.	Lorenzen S,Blank S,Lordick F,et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol,2012,19(7):2119-2127.
19.	Becker K,Langer R,Reim D,et al.Significance of histopatho-logical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas:a summary of 480 cases[J].Ann Surg,2011,253(5):934-939.
20.	Kucukoner M,Isikdogan A,Arpaci E,et al.Adjuvant chemora-diation for gastric cancer:multicentric study of the Anatolian Soc-iety of Medical Oncology[J].Hepatogastroenterology,2012,59(119):2343-2347.
21.	Kucukoner M,Arpaci E,Isikdogan A,et al.Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy[J].Neoplasma,2013,60(1):19-25.
22.	Yonemura Y,Ninomiya I,Yamaguchi A,et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer[J].Cancer Res,1991,51(3):1034-1038.
23.	Kataoka Y,Okabe H,Yoshizawa A,et al.HER2 expression and its clinicopathological features in resectable gastric cancer[J].Gastric Cancer,2013,16(1):84-93.
24.	Aizawa M,Nagatsuma AK,Kitada K,et al.Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population[J].Gastric Cancer,2013 Feb 22.[Epub ahead of print].
25.	Zhou F,Li N,Jiang W,et al.Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curati-vely resected gastric cancer after the ToGA clinical trial[J].World J Surg Oncol,2012,10:274.
26.	Jorgensen JT.Targeted HER2 treatment in advanced gastric cancer[J].Oncology,2010,78(1):26-33.
27.	Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
28.	Tanner M,Hollmen M,Junttila TT,et al.Amplification of HER-2 in gastric carcinoma:association with Topoisomerase Ⅱalpha gene amplification,intestinal type,poor prognosis and sensitivity to trastuzumab[J].Ann Oncol,2005,16(2):273-278.
29.	Fan XS,Chen JY,Li CF,et al.Differences in HER2 over-exp-ression between proximal and distal gastric cancers in the Chinese population[J].World J Gastroenterol,2013,19(21):3316-3323.
30.	Marx AH,Tharun L,Muth J,et al.HER-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2009,40(6):769-777.
31.	Jorgensen JT,Hersom M.HER2 as a prognostic marker in gastric cancer:a systematic analysis of data from the literature[J].J Cancer,2012,3:137-144.
32.	Okines AF,Cunningham D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949-1959.
33.	Okines AF,Cunningham D.Trastuzumab:a novel standard opt-ion for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer[J].Therap Adv Gastroenterol,2012,5(5):301-318.
34.	Rüschoff J,Hanna W,Bilous M,et al.HER2 testing in gastric cancer:a practical approach[J].Mod Pathol,2012,25(5):637-650.
35.	Sun Z,Wang ZN,Zhu Z,et al.Evaluation of the seventh edit-ion of American Joint Committee on Cancer TNM staging system for gastric cancer:results from a Chinese monoinstitutional study[J].Ann Surg Oncol,2012,19(6):1918-1927.
36.	Reim D,Loos M,Vogl F,et al.Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer:the Western experience of patients treated in a single-center European institution[J].J Clin Oncol,2013,31(2):263-271.
37.	Yoon HM,Ryu KW,Nam BH,et al.Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer?[J].J Am Coll Surg,2012,214(1):88-96.
38.	Strong VE,D'Amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66.
39.	Isomoto H,Shikuwa S,Yamaguchi N,et al.Endoscopic submu-cosal dissection for early gastric cancer:a large-scale feasibility study[J].Gut,2009,58(3):331-336.
40.	Chen XZ,Hu JK,Yang K,et al.Short-term evaluation of lapar-oscopy-assisted distal gastrectomy for predictive early gastric cancer:a meta-analysis of randomized controlled trials[J].Surg Laparosc Endosc Percutan Tech,2009,19(4):277-284.
41.	Chen XZ,Li YY,Hu JK,et al.Spread and development of laparoscopic surgery for gastric tumors in mainland China:initial experiences[J].Hepatogastroenterology,2012,59(114):654-658.
42.	Wen L,Chen XZ,Wu B,et al.Total vs. proximal gastrectomy for proximal gastric cancer:a systematic review and meta-analysis[J].Hepatogastroenterology,2012,59(114):633-640.
43.	Chen XZ,Yang K,Liu J,et al.Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer[J].World J Gastroenterol,2011,17(40):4542-4544.
44.	胡建昆,陈心足.食管胃结合部腺癌围手术期放化疗合理应用及评价[J].中国实用外科杂志,2012,32(4):303-306.
45.	Schuhmacher C,Gretschel S,Lordick F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218.
46.	Hu JK,Li CM,Chen XZ,et al.The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma:A systematic review of published randomi-zed controlled trials[J].J Chemother,2007,19(4):359-375.
47.	Paoletti X,Oba K,Burzykowski T,et al.Benefit of adjuvant chemotherapy for resectable gastric cancer:a meta-analysis[J].JAMA,2010,303(17):1729-1737.
48.	National Comprehensive Cancer Network.Gastric Cancer (Inclu-ding cancer in the proximal 5 cm of the stomach) Version 2.2013.NCCN Clinical Practice Guilelines in Oncology 2013[EB/OL].http://www.nccn.org.
49.	Fiori E,Lamazza A,Demasi E,et al.Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pylo-ric cancer.Systematic review of the literature and final results of a prospective study.The point of view of a surgical group[J].Am J Surg,2013,206(2):210-217.

1. 胡建昆,陈心足.进展期胃癌治疗方式合理选择及评价[J].中国实用外科杂志,2011,31(8):720-722.
2. 胡建昆,陈心足.胃癌多学科协作诊疗模式现状[J].中国普外基础与临床杂志,2012,19(1):1-3.
3. Hu B,El Hajj N,Sittler S,et al.Gastric cancer:Classification,histology and application of molecular pathology[J].J Gastrointest Oncol,2012,3(3):251-261.
4. 何裕隆.胃癌病理分型研究进展[J].中国实用外科杂志,2005,25(7):438-440.
5. Santiago JM,Sasako M,Osorio J.TNM-7th edition 2009(UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer.Tow-ards simplicity and standardisation in the management of gastric cancer[J].Cir Esp,2011,89(5):275-281.
6. Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2011,14(2):113-123.
7. Liang YX,Guo HH,Deng JY,et al.Impact of intraoperative blood loss on survival after curative resection for gastric cancer[J].World J Gastroenterol,2013,19(33):5542-5550.
8. Yang B,Wu G,Wang X,et al.Discussion of modifying stage Ⅳ gastric cancer based on Borrmann classification[J].Tumour Biol,2013,34(3):1485-1491.
9. Sun XC,Lin J,Ju AH.Treatment of Borrmann type Ⅳ gastric cancer with a neoadjuvant chemotherapy combination of docetaxel,cisplatin and 5-fluorouracil/leucovorin[J].J Int Med Res,2011,39(6):2096-2102.
10. Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459.
11. Sasako M,Sano T,Yamamoto S,et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial[J].Lancet Oncol,2006,7(8):644-651.
12. Mine S,Sano T,Hiki N,et al.Proximal margin length with trans-hiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction[J].Br J Surg,2013,100(8):1050-1054.
13. Lauren P.The two histological main types of gastric carcinoma:Diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification[J].Acta Pathol Microbiol Scand,1965,64:31-49.
14. Lauwers GY,Carneiro F,Graham DY.Gastric carcinoma[A]//Bowman FT,Carneiro F,Hruban RH,eds.Classification of tumours of the digestive system[M].Lyon:IARC,2010.In press.
15. 李忠武,曹登峰.胃癌病理分型与临床个体化治疗——问题与展望[J].中国医学前沿杂志:电子版,2012,4(5):15-20.
16. Liu L,Wang ZW,Ji J,et al.A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma[J].Anticancer Agents Med Chem,2013,13(2):227-234.
17. Qiu MZ,Cai MY,Zhang DS,et al.Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China[J].J Transl Med,2013,11:58.
18. Lorenzen S,Blank S,Lordick F,et al.Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients[J].Ann Surg Oncol,2012,19(7):2119-2127.
19. Becker K,Langer R,Reim D,et al.Significance of histopatho-logical tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas:a summary of 480 cases[J].Ann Surg,2011,253(5):934-939.
20. Kucukoner M,Isikdogan A,Arpaci E,et al.Adjuvant chemora-diation for gastric cancer:multicentric study of the Anatolian Soc-iety of Medical Oncology[J].Hepatogastroenterology,2012,59(119):2343-2347.
21. Kucukoner M,Arpaci E,Isikdogan A,et al.Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy[J].Neoplasma,2013,60(1):19-25.
22. Yonemura Y,Ninomiya I,Yamaguchi A,et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer[J].Cancer Res,1991,51(3):1034-1038.
23. Kataoka Y,Okabe H,Yoshizawa A,et al.HER2 expression and its clinicopathological features in resectable gastric cancer[J].Gastric Cancer,2013,16(1):84-93.
24. Aizawa M,Nagatsuma AK,Kitada K,et al.Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population[J].Gastric Cancer,2013 Feb 22.[Epub ahead of print].
25. Zhou F,Li N,Jiang W,et al.Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curati-vely resected gastric cancer after the ToGA clinical trial[J].World J Surg Oncol,2012,10:274.
26. Jorgensen JT.Targeted HER2 treatment in advanced gastric cancer[J].Oncology,2010,78(1):26-33.
27. Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
28. Tanner M,Hollmen M,Junttila TT,et al.Amplification of HER-2 in gastric carcinoma:association with Topoisomerase Ⅱalpha gene amplification,intestinal type,poor prognosis and sensitivity to trastuzumab[J].Ann Oncol,2005,16(2):273-278.
29. Fan XS,Chen JY,Li CF,et al.Differences in HER2 over-exp-ression between proximal and distal gastric cancers in the Chinese population[J].World J Gastroenterol,2013,19(21):3316-3323.
30. Marx AH,Tharun L,Muth J,et al.HER-2 amplification is highly homogenous in gastric cancer[J].Hum Pathol,2009,40(6):769-777.
31. Jorgensen JT,Hersom M.HER2 as a prognostic marker in gastric cancer:a systematic analysis of data from the literature[J].J Cancer,2012,3:137-144.
32. Okines AF,Cunningham D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949-1959.
33. Okines AF,Cunningham D.Trastuzumab:a novel standard opt-ion for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer[J].Therap Adv Gastroenterol,2012,5(5):301-318.
34. Rüschoff J,Hanna W,Bilous M,et al.HER2 testing in gastric cancer:a practical approach[J].Mod Pathol,2012,25(5):637-650.
35. Sun Z,Wang ZN,Zhu Z,et al.Evaluation of the seventh edit-ion of American Joint Committee on Cancer TNM staging system for gastric cancer:results from a Chinese monoinstitutional study[J].Ann Surg Oncol,2012,19(6):1918-1927.
36. Reim D,Loos M,Vogl F,et al.Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer:the Western experience of patients treated in a single-center European institution[J].J Clin Oncol,2013,31(2):263-271.
37. Yoon HM,Ryu KW,Nam BH,et al.Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer?[J].J Am Coll Surg,2012,214(1):88-96.
38. Strong VE,D'Amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66.
39. Isomoto H,Shikuwa S,Yamaguchi N,et al.Endoscopic submu-cosal dissection for early gastric cancer:a large-scale feasibility study[J].Gut,2009,58(3):331-336.
40. Chen XZ,Hu JK,Yang K,et al.Short-term evaluation of lapar-oscopy-assisted distal gastrectomy for predictive early gastric cancer:a meta-analysis of randomized controlled trials[J].Surg Laparosc Endosc Percutan Tech,2009,19(4):277-284.
41. Chen XZ,Li YY,Hu JK,et al.Spread and development of laparoscopic surgery for gastric tumors in mainland China:initial experiences[J].Hepatogastroenterology,2012,59(114):654-658.
42. Wen L,Chen XZ,Wu B,et al.Total vs. proximal gastrectomy for proximal gastric cancer:a systematic review and meta-analysis[J].Hepatogastroenterology,2012,59(114):633-640.
43. Chen XZ,Yang K,Liu J,et al.Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer[J].World J Gastroenterol,2011,17(40):4542-4544.
44. 胡建昆,陈心足.食管胃结合部腺癌围手术期放化疗合理应用及评价[J].中国实用外科杂志,2012,32(4):303-306.
45. Schuhmacher C,Gretschel S,Lordick F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218.
46. Hu JK,Li CM,Chen XZ,et al.The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma:A systematic review of published randomi-zed controlled trials[J].J Chemother,2007,19(4):359-375.
47. Paoletti X,Oba K,Burzykowski T,et al.Benefit of adjuvant chemotherapy for resectable gastric cancer:a meta-analysis[J].JAMA,2010,303(17):1729-1737.
48. National Comprehensive Cancer Network.Gastric Cancer (Inclu-ding cancer in the proximal 5 cm of the stomach) Version 2.2013.NCCN Clinical Practice Guilelines in Oncology 2013[EB/OL].http://www.nccn.org.
49. Fiori E,Lamazza A,Demasi E,et al.Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pylo-ric cancer.Systematic review of the literature and final results of a prospective study.The point of view of a surgical group[J].Am J Surg,2013,206(2):210-217.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Treatment and Prognosis Based on Types and Stages of Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content